Roivant to Report Financial Results for the Third Quarter Ended December 31, 2023, and Provide Business Update on Tuesday, February 13, 2024
BASEL, Switzerland and LONDON and NEW YORK, Jan. 30, 2024 (GLOBE NEWSWIRE) -- Roivant (Nasdaq: ROIV) today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Tuesday,
Roche Completes Acquisition of Telavant From Roivant, Including Rights to Novel TL1A Directed Antibody (RVT-3101) for the Treatment of Inflammatory Bowel Disease
BASEL, Switzerland and LONDON and NEW YORK, Dec. 14, 2023 (GLOBE NEWSWIRE) -- Roivant (Nasdaq: ROIV) announced today the completion of the previously announced acquisition by Roche (SIX: RO, ROG; OT
Roivant and Priovant Announce Results From Phase 2 Study of Oral Brepocitinib in Systemic Lupus Erythematosus
Oral brepocitinib failed to meet its primary endpoint of Systemic Lupus Erythematosus Responder Index (SRI-4) change of 4 at Week 52Priovant plans to continue progressing the program in indications ou
Roivant Announces Appointment of Mayukh Sukhatme to Its Board of Directors
BASEL, Switzerland and LONDON and NEW YORK, Nov. 10, 2023 (GLOBE NEWSWIRE) -- Roivant (Nasdaq: ROIV) today announced the appointment of Mayukh Sukhatme, M.D., to its Board of Directors, effective im
Roivant to Report Financial Results for the Second Quarter Ended September 30, 2023, and Provide Business Update on Monday, November 13, 2023
BASEL, LONDON, and NEW YORK, Oct. 30, 2023 (GLOBE NEWSWIRE) -- Roivant (Nasdaq: ROIV) today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Monday, November 13, 202
Roivant Announces Completion of Redemption of Its Outstanding Warrants
BASEL, Switzerland and LONDON and NEW YORK, Sept. 11, 2023 (GLOBE NEWSWIRE) -- Roivant (NASDAQ:ROIV) today announced that it completed the redemption of its outstanding public warrants (the "Public Warrants") and
Presidential Hopeful Ramaswamy Predicts US Recession In 2024
In a recent interview with Tucker Carlson on X, presidential hopeful Vivek Ramaswamy spotlighted concerns about an impending U.S. recession in 2024, leaning heavily on historical indicators.What Happe
Roivant Announces Redemption Fair Market Value in Connection With Redemption of Its Outstanding Warrants
Roivant Sciences GAAP EPS of -$0.38 Misses by $0.07, Revenue of $21.62M Misses by $2.87M
STAA, OM and ROIVW Are Among After Hour Movers
Roivant Announces Redemption of Outstanding Warrants
BASEL, Switzerland and LONDON and NEW YORK, Aug. 02, 2023 (GLOBE NEWSWIRE) -- Roivant (Nasdaq: ROIV) today announced that it will redeem all of its outstanding public warrants (the "Public Warrants"
Telavant, a Roivant Company, Advances Inflammatory Bowel Disease Program With First Patient Dosed in Global Phase 2 Trial of Novel Anti-TL1A Antibody RVT-3101 in Crohn's Disease
The Phase 2 TAHOE study, which is currently enrolling, evaluates the safety and efficacy of RVT-3101 in patients with moderate to severely active Crohn's disease (CD)Roivant recently announced highly
Roivant Ranks No. 25 on Fast Company's Fifth Annual List of the 100 Best Workplaces for Innovator...
Roivant to Report Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2023, and Provide Business Update on Wednesday, June 28, 2023
BASEL, Switzerland and LONDON and NEW YORK and BOSTON, June 26, 2023 (GLOBE NEWSWIRE) -- Roivant Sciences (Nasdaq: ROIV) today announced that it will host a live conference call and webcast at 8:00
Roivant Reports Chronic Period Data for RVT-3101 From the TUSCANY-2 Phase 2b Study in Ulcerative Colitis, Demonstrating Improved Efficacy From the Induction to Chronic Period
This is the first-ever long-duration data reported for an anti-TL1A antibodyAt the expected Phase 3 once-monthly subcutaneous dose in the overall population, RVT-3101 treatment resulted in improved Clinical Remission1
Roivant to Host Investor Call at 8:00 AM ET on Thursday, June 22 to Review Results From the Chronic Period of TUSCANY-2, a Large Global Phase 2b Study of RVT-3101 (Anti-TL1A Antibody) in Ulcerative Colitis
BASEL, Switzerland and LONDON and NEW YORK and BOSTON, June 21, 2023 (GLOBE NEWSWIRE) -- Roivant Sciences (NASDAQ:ROIV) today announced that it will host a live investor call and webcast at 8:00 AM ET on Thursday, June
Covant and Boehringer Ingelheim Collaborate to Develop a Novel ADAR1 Inhibitor for Use in Cancer Patients
BOSTON, March 28, 2023 (GLOBE NEWSWIRE) -- Covant Therapeutics, an innovative covalent drug discovery company, has entered into an exclusive research collaboration and worldwide licensing agreement
Roivant Reports Positive Topline Results From ADORING 2 Atopic Dermatitis Phase 3 Trial of VTAMA (Tapinarof) Cream, 1% Once Daily in Adults and Children as Young as 2 Years Old
46.4% of subjects receiving VTAMA cream, 1% achieved the primary endpoint of Validated Investigator Global Assessment for Atopic Dermatitis (vIGA-ADTM) response of clear (0) or almost clear (1) with a
Roivant to Host Investor Call at 8:00 AM ET on Wednesday, March 15 to Review Results From ADORING 2 Phase 3 Trial in Atopic Dermatitis
BASEL, Switzerland and LONDON and NEW YORK and BOSTON, March 14, 2023 (GLOBE NEWSWIRE) -- Roivant Sciences (Nasdaq: ROIV) today announced that it will host a live investor call and webcast at 8:00 A
Proteovant Therapeutics to Present Preclinical Data From Estrogen Receptor and IKZF2 Protein Degrader Programs
PVTX-321 and PVTX-405 Achieve Development Candidate NominationNEW YORK, March 14, 2023 (GLOBE NEWSWIRE) -- Proteovant Therapeutics, a Roivant Sciences (Nasdaq: ROIV) company leveraging the process o
No Data